CEDARS-SINAI ALERT COVID-19 (coronavirus)

INFORMATION AND UPDATES FOR PATIENTS AND VISITORS

3rd Street Diagnostics

Diagnostic targets and biomarkers make up approximately 25 percent of the Cedars-Sinai intellectual property portfolio. The majority of these assets are related to small patient populations and, for various reasons, face unique challenges with traditional technology transfer.

Thus, Cedars-Sinai's Technology Ventures developed an in-house diagnostic development business unit known as 3rd Street Diagnostics. Its purpose is to evaluate technologies in the Cedars-Sinai portfolio or to in-license particularly attractive assets. 3rd Street Diagnostics then identifies industry partners with the expertise required to facilitate a project. Ultimately, the goal is to collaborate and commercialize technologies from both Cedars-Sinai and our international partners.

Open Call for Diagnostics

Technology Ventures is interested in facilitating molecular diagnostic technologies that utilize:

  • Deoxyribonucleic acid (DNA) sequencing¬†
  • Ribonucleic acid (RNA) expression¬†
  • Single and multiplex protein-based assays and cell-based tests

Have Questions or Need Help?

Contact us if you have questions or wish to learn more about Technology & Innovations at Cedars-Sinai.